A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,882,197 shares of PCRX stock, worth $53.4 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
1,882,197
Previous 1,716,697 9.64%
Holding current value
$53.4 Million
Previous $57.9 Million 5.05%
% of portfolio
0.09%
Previous 0.09%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$27.7 - $35.48 $4.58 Million - $5.87 Million
165,500 Added 9.64%
1,882,197 $55 Million
Q4 2023

Feb 13, 2024

BUY
$26.32 - $34.31 $2.7 Million - $3.52 Million
102,700 Added 6.36%
1,716,697 $57.9 Million
Q3 2023

Nov 14, 2023

BUY
$30.68 - $40.09 $1.21 Million - $1.58 Million
39,300 Added 2.5%
1,613,997 $49.5 Million
Q2 2023

Aug 11, 2023

BUY
$36.12 - $47.5 $570,696 - $750,500
15,800 Added 1.01%
1,574,697 $63.1 Million
Q1 2023

May 12, 2023

SELL
$35.53 - $43.38 $1 Million - $1.22 Million
-28,200 Reduced 1.78%
1,558,897 $63.6 Million
Q4 2022

Feb 13, 2023

SELL
$38.19 - $57.45 $6.35 Million - $9.56 Million
-166,400 Reduced 9.49%
1,587,097 $61.3 Million
Q3 2022

Nov 14, 2022

SELL
$51.24 - $58.89 $10.9 Million - $12.5 Million
-212,000 Reduced 10.79%
1,753,497 $93.3 Million
Q2 2022

Aug 12, 2022

BUY
$51.49 - $81.64 $5.38 Million - $8.53 Million
104,500 Added 5.62%
1,965,497 $115 Million
Q1 2022

May 13, 2022

BUY
$60.03 - $76.49 $708,354 - $902,581
11,800 Added 0.64%
1,860,997 $142 Million
Q4 2021

Feb 11, 2022

SELL
$47.97 - $62.21 $5.74 Million - $7.44 Million
-119,600 Reduced 6.07%
1,849,197 $111 Million
Q3 2021

Nov 12, 2021

SELL
$54.64 - $61.3 $5 Million - $5.61 Million
-91,530 Reduced 4.44%
1,968,797 $110 Million
Q2 2021

Aug 13, 2021

SELL
$59.18 - $69.99 $15.1 Million - $17.8 Million
-254,470 Reduced 10.99%
2,060,327 $125 Million
Q1 2021

May 13, 2021

SELL
$59.31 - $78.82 $18.4 Million - $24.5 Million
-310,262 Reduced 11.82%
2,314,797 $162 Million
Q4 2020

Feb 10, 2021

SELL
$50.47 - $66.26 $7.82 Million - $10.3 Million
-155,038 Reduced 5.58%
2,625,059 $157 Million
Q3 2020

Nov 13, 2020

SELL
$51.97 - $63.0 $3.67 Million - $4.45 Million
-70,700 Reduced 2.48%
2,780,097 $167 Million
Q2 2020

Aug 13, 2020

BUY
$30.8 - $52.47 $11.8 Million - $20.1 Million
382,655 Added 15.5%
2,850,797 $150 Million
Q1 2020

May 14, 2020

BUY
$28.4 - $50.7 $19.1 Million - $34 Million
670,804 Added 37.32%
2,468,142 $82.8 Million
Q4 2019

Feb 13, 2020

BUY
$36.31 - $46.83 $21.1 Million - $27.3 Million
582,238 Added 47.92%
1,797,338 $81.4 Million
Q3 2019

Nov 13, 2019

BUY
$35.66 - $44.99 $4.38 Million - $5.53 Million
122,900 Added 11.25%
1,215,100 $46.3 Million
Q2 2019

Aug 12, 2019

BUY
$36.57 - $47.97 $1.05 Million - $1.37 Million
28,600 Added 2.69%
1,092,200 $47.5 Million
Q1 2019

May 14, 2019

BUY
$36.47 - $42.17 $25.8 Million - $29.9 Million
708,300 Added 199.35%
1,063,600 $40.5 Million
Q4 2018

Feb 13, 2019

BUY
$41.31 - $52.16 $14.7 Million - $18.5 Million
355,300 New
355,300 $15.3 Million

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $1.3B
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.